Prefilled syringes containing an injectable volume of 0.8 ml solution for injection ADA for single use at dosage strength of 40 mg/0.8 ml.
Injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal.
Subjects must be on MTX 15 to 25 mg/week orally or subcutaneously and maintain the same route of administration from Baseline through Week 104. For subjects who cannot tolerate MTX at doses between 15 to 25 mg/week, the dose may be reduced to 10 mg/week orally or subcutaneously.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01500278?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
